Background: Myasthenia gravis (MG) is an autoimmune neuromuscular disorder mediated by antibodies targeting components of the postsynaptic membrane at the neuromuscular junction. Up to 15% of patients develop refractory disease despite standard immunotherapies. Current guidelines recommend rituximab as a first-line opt...
Amanda Vitória Freire de Oliveira, Beatriz Carneiro Gondim Silva, Renata Andrade et al.· ANPAbstract_CBN26· 0 citations
Focal phenotypes represent uncommon initial presentations of myasthenia gravis and may delay diagnosis, and patients who initially presented with distal upper limb weakness maintained this pattern as the predominant clinical manifestation even after generalization.
Amanda Vitória Freire de Oliveira, Manoella Guerra de Albuquerque Bueno, André Cleriston José dos Santos et al.· ANPAbstract_CBN26· 0 citations
Background: Myasthenia gravis (MG) is an autoimmune disorder characterized by fluctuating skeletal muscle weakness and fatigability due to impaired neuromuscular transmission. Its clinical expression is heterogeneous. The epidemiology, age at onset, patterns of clinical involvement, and disease trajectory vary across p...
Amanda Vitória Freire de Oliveira, Lucas Grobério Moulim, Manoella Guerra de Albuquerque Bueno et al.· ANPAbstract_CBN26· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.